The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy-Reference-Cited by-同舟云学术

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

Published:2019-02-08 Issue:5 Volume:195 Page:430-440
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:en
Short-container-title:Strahlenther Onkol

Author:

Poetsch Nina^ORCID,Sturdza Alina,Aust Stefanie,Polterauer Stephan,Grimm Christoph^ORCID,Schwameis Richard^ORCID,Pötter Richard,Koelbl Heinz,Reinthaller Alexander^ORCID,Seebacher Veronika^ORCID

Funder

Medical University of Vienna

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/article/10.1007/s00066-019-01430-z/fulltext.html

Reference43 articles.

1. Sankaranarayanan R, Nene BM, Shastri SS et al (2009) HPV screening for cervical cancer in rural India. N Engl J Med 360:1385–1394. https://doi.org/10.1056/NEJMoa0808516

2. Collaboration C for cervical cancer meta-analysis (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802–5812. https://doi.org/10.1200/JCO.2008.16.4368

3. Pearcey R, Brundage M, Drouin P et al (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20:966–972. https://doi.org/10.1200/JCO.2002.20.4.966